Earnings Outlook For Axsome Therapeutics
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) is scheduled to release its quarterly earnings report on February 20, 2024, with an estimated EPS of $-1.15. Despite past earnings misses, the company's stock has shown resilience with a 46.25% increase over the last 52 weeks. Investors are keen on the upcoming guidance for future growth.
February 19, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics is expected to report a Q4 EPS of $-1.15. Despite previous misses, the stock has increased by 46.25% over the past year, indicating strong investor confidence.
Given Axsome Therapeutics' resilience in stock performance despite past earnings misses, and a significant 46.25% increase over the last year, investor sentiment appears positive. The anticipation of future guidance, which is a critical factor for stock movement post-earnings, suggests a potential positive short-term impact on AXSM's stock price, especially if the company beats the EPS estimate or provides strong future guidance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100